ArticleScientific reports2026
Chemotherapy-derived DAMPs drive reprogramming of tumor-associated macrophages toward a pro-inflammatory phenotype in hepatocellular carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Remodeling the Immune Landscape: How Obesity-Induced SASPs Create a Pro-Tumorigenic Niche.Current obesity reports · 2026Review
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) remains a global health challenge, with treatment efficacy often compromised by the immunosuppressive tumor microenvironment (TME), particularly tumor-associated macrophages (TAMs). While chemotherapy induces immunogenic cell death (ICD) and the release of Damage-Associated Molecular Patterns (DAMPs), the specific impact of these molecules on macrophage plasticity and the underlying signaling mechanisms remain poorly understood. This study investigated the immunomodulatory effects of DAMPs released from HepG2 cells treated with standard chemotherapeutic agents, sorafenib and oxaliplatin. Macrophage polarization was assessed using murine RAW 264.7 and human monocyte-derived macrophages. The current study utilized flow cytometry, multiplex cytokine profiling, immunoblotting, and proteomic analysis to characterize phenotypic shifts and signaling pathways. Both Sorafenib and oxaliplatin induced significant cytotoxicity and the release of HMGB1 and S100A9, while sorafenib specifically triggered HSP90 release. Exposure to these chemotherapy-derived DAMPs effectively reprogrammed IL-4 stimulated M2 macrophages toward an M1-like phenotype, evidenced by downregulation of CD163/CD206, and upregulation of CD86. Mechanistically, this reprogramming was driven by a distinct, non-canonical signaling axis involving the upregulation of p-ERK and the NLRP3 inflammasome, occurring despite the downregulation of the classical NF-κB pathway. Proteomic analysis further revealed a metabolic shift toward cellular stress, ER stress and transcriptional reprogramming. Although the cytokine profile was predominantly pro-inflammatory (TNF-α, IL-1β), the concurrent secretion of IL-10 suggests a complex, mixed activation state. By overriding M2 immunosuppression via an ERK-NLRP3-dependent pathway, sorafenib-derived DAMPs act as an immunological primer to convert cold to hot tumors, providing a molecular rationale for chemo-immunotherapy combinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.